Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007487 | 0.89 | MAPT (0.80) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL8761088 | 0.88 | MAPT (0.66) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL5674481 | 0.86 | MAPT (0.76) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL27930584 | 0.85 | L3MBTL1 (0.59) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL9007485 | 0.81 | TSHR (0.62) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL27910258 | 0.80 | MAPT (0.67) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL1952637 | 0.80 | HTR1A (0.51) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL19612191 | 0.79 | MAPT (1.00) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL9340084 | 0.79 | MAPT (0.65) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL31725934 | 0.79 | MAPT (0.65) | MAPTTDP1L3MBTL1MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| CN-101115734-A | Spiro derivatives as lipoxygenase inhibitors | LILLY CO ELI (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| CN-1247509-C | Method for producing chroman | KURARAY CO (JP) | 2006-03-29 | — | — | CN | disclosed |
| CN-1394837-A | Method for producing chroman | KURARAY CO (JP) | 2003-02-05 | — | — | CN | disclosed |
| CN-1088066-C | Process for producing chromans | KURARAY CO (JP) | 2002-07-24 | — | — | CN | disclosed |
| EP-0891974-B1 | Process for producing chromans | KURARAY CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6133471-A | Process for producing chromans | KURARAY CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6130341-A | Process for producing chromans | KURARAY CO., LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| CN-1206007-A | Process for producing chromans | KURARAY CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| EP-0891974-A1 | Process for producing chromans | KURARAY CO., LTD. (JP) | 1999-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | MAPT 4822/4885TDP1 3249/4885L3MBTL1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.